G6PD Test – Glucose 6 Phosphate Dehydrogenase Test

I am a returning customer
I want this for my family

Product Description

Glucose-6-phosphate dehydrogenase deficiency (G6PD deficiency) also known as favism (after the fava bean) is an X-linked (hence predominantly seen in men) recessive genetic condition that predisposes to haemolysis (spontaneous destruction of red blood cells) and resultant jaundice in response to a number of triggers, such as certain foods, illness, or medication.
G6PD deficiency is characterized by abnormally low levels of glucose-6-phosphate dehydrogenase, an enzyme involved in the pentose phosphate pathway that is especially important in the red blood cell. G6PD deficiency is the most common human enzyme defect. There is no specific treatment, other than avoiding known triggers.
G6PD enzyme testing is primarily performed when an individual has signs and symptoms associated with haemolytic anaemia. Testing may be done when someone has had an episode of increased red cell destruction (haemolytic crisis) but after the crisis has resolved.
A doctor may also order the test if he is to put you under certain medications that are known to trigger haemolysis if you suffer from G6PD deficiency and are not aware of the conditions

FeatureValue
SpecimenSerum (Blood)
Related TestsCBC, Blood Smear, Reticulocyte Count, Bilirubin, RBC Count, Hemoglobin, Heinz Body Stain
Schedule Visit
Opt for Metropolis, The Pathology Specialist
The Metropolis Edge

The Metropolis Edge

  • Report trusted by Doctors.
  • Global & National Quality Accreditations – CAP (USA) and NABL , Govt. of India.
  • Guaranteed error free diagnosis.
  • Bar Coded and automated process. No room for manual errors.
  • Specific normal range for Indian population built from 33 years of experience.
  • Sample collection from home/office.
Metropolis: Experience + Expertise

Metropolis: Experience + Expertise

Over the past 3 decades we have earned the respect of doctors and patients. Today we conduct over 30 million tests annually with accuracy each year. Our repertoire extends over 4500 tests and over 100 different technologies. Our customer care is available round the clock for any queries that you may have.

Reach out to our Counsellors
Comprehensive Analysis Of Your Health
Save tax on the Preventive health check-ups up to Rs. 5000, under section 80D of Income Tax Act, 1961
We are Metropolis - Your Pathology Specialist

Metropolis is one of the leading diagnostics companies in India, by revenue, as of March 31, 2018 (Source: Frost & Sullivan). With operations across India, Africa, South Asia and Middle East.

Our globally accredited clinical laboratories deliver millions of accurate and timely test results every year. We offer a comprehensive range of clinical laboratory tests and profiles which are used in prediction, early detection, diagnostic screening, confirmation and monitoring of diseases.

 

  • Delivering diagnostic services since 1980
  • Network of 100+ clinical labs & 1100+ patient touch points
  • Qualified team of phlebotomists for Home collection services

 

  • Certified NABL and CAP accredited labs
  • Wide range of 4000+ tests & profiles
  • Convenience of home collection service

 

Metropolis Healthcare Limited is proposing subject to applicable statutory or regulatory requirements, receipt of requisite approvals, market conditions and other considerations to undertake an initial public offering of its equity shares and has filed a draft red herring prospectus dated September 27, 2018 (“DRHP”) with the Securities and Exchange Board of India (“SEBI”). The DRHP is available on the website of the SEBI at www.sebi.gov.in, BSE Limited at www.bseindia.com, National Stock Exchange of India Limited at www.nseindia.com and the websites of Book Running Lead Managers at www.jmfl.com, www.credit-suisse.com, www.investmentbank.kotak.com, www.hdfcbank.com and www.goldmansachs.com. Any potential investors should note that investment in equity shares involves a high degree of risk and for details relating to same, please refer to the DRHP including the section “Risk Factors” of the DRHP. Potential investors should not rely on the DRHP filed with the SEBI for making any investment decision.

 

Scroll Up